KAIST spin-off developing PEGylated bilirubin BX-001N to prevent acute kidney injury after cardiac surgery, now in phase 2a in Korea.
Korean acute-kidney-injury drug in phase 2a: clinical-stage biotech like BioSapien.
Evidence from the records
- “Drug for acute kidney injury”
- “phase 2a under way in Korea”
- Intro path
- BioSapien (Dara portfolio)
- First step
- Ask BioSapien for an intro.